News

Positive Clinical Data on INOpulse® Presented at the American Thoracic Society 113th International Conference

WARREN, N.J., May 22, 2017 (GLOBE NEWSWIRE) — Bellerophon Therapeutics, Inc. (BLPH), a clinical-stage biotherapeutics company, today announced the presentation of new clinical data from a Phase 2 clinical trial that investigated INOpulse in idiopathic pulmonary fibrosis patients with pulmonary hypertension (PH-IPF) at the American Thoracic Society (ATS) 113th International Conference, currently taking place in Washington DC.  The company also presented preliminary data from a second, ongoing study evaluating INOpulse in COPD patients with Pulmonary Hypertension (PH-COPD).

2017-06-20T13:05:34+00:00